Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)

K Callis Duffin, J Bagel, M Bukhalo, I J Mercado Clement, S L Choi, F Zhao, A Gill, B Pangallo, C Shuler, L Mallbris, K Jackson, K Callis Duffin, J Bagel, M Bukhalo, I J Mercado Clement, S L Choi, F Zhao, A Gill, B Pangallo, C Shuler, L Mallbris, K Jackson

Abstract

Background: The efficacy of ixekizumab, an anti-interleukin-17A (anti-IL-17A) monoclonal IgG4 antibody, was demonstrated in moderate-to-severe psoriasis patients when administered via prefilled syringe (PFS).

Objective: To evaluate the effect of two drug delivery devices on the pharmacokinetics (PK) of ixekizumab as well as efficacy and safety with both devices.

Methods: In the first 12 weeks of an open-label, phase 3 study, moderate-to-severe psoriasis patients were randomized to ixekizumab delivery via PFS or autoinjector device. Randomization was stratified by weight (<80 kg, 80-100 kg, >100 kg), injection assistance (yes/no) and injection site (arm, thigh or abdomen). Following a 160-mg initial dose at week 0, patients received subcutaneous 80-mg ixekizumab as a single injection every 2 weeks for 12 weeks. Blood samples were collected following the initial 160-mg dose on days 2, 4, 7, 10 and 14 for PK analysis. Primary PK parameters were maximum concentration (Cmax ) and area under the curve (AUC0-tlast ) where tlast is the time of last sample (14 days ± 24 h). Efficacy was assessed by percent improvement on the Psoriasis Area and Severity Index (PASI) at week 12. Adverse event reporting, vital signs and clinical laboratory data were used to evaluate safety.

Results: Of 204 randomized patients, 192 were included in the PK analysis (PFS: 94; autoinjector: 98). The PFS and autoinjector showed similar geometric mean Cmax (90% CI) [15.0 μg/mL (13.9-16.1) vs. 14.8 μg/mL (13.8-15.9)] and geometric mean AUC0-tlast (90% CI) [157 μg × day/mL (147-168) vs. 154 μg × day/mL (144-165)]. When comparing Cmax and AUC0-tlast of the autoinjector to PFS, the geometric LS mean ratios were 0.97. At week 12, mean percent PASI improvement (via modified baseline observation carried forward) was similar with the PFS (89.3%) and autoinjector (86.9%). Both devices had safety results that were consistent with the known safety profile of ixekizumab.

Conclusion: The PK, efficacy and safety of ixekizumab administered subcutaneously by PFS and autoinjector were similar. Clinicaltrials.gov number: NCT01777191 https://ichgcp.net/clinical-trials-registry/NCT01777191.

© 2016 The Authors. Journal of European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Figures

Figure 1
Figure 1
cStudy design for administration of ixekizumab via a prefilled syringe or autoinjector. 80 mg Q2W, 80‐mg ixekizumab every 2 weeks; PK, pharmacokinetic; SC, subcutaneous; W, week; V, visit.
Figure 2
Figure 2
Patient disposition for all patients randomized to ixekizumab treatment via prefilled syringe or autoinjector and for PK‐evaluable patients (patients who were compliant with the dosing regimen and PK sampling scheme, and patients who had at least four serum samples and were not missing the last sample on day 14). PK, pharmacokinetic; 80 mg Q2W, 80‐mg ixekizumab every 2 weeks.
Figure 3
Figure 3
Mean (±SD) serum ixekizumab concentration vs. time profiles following a 160‐mg subcutaneous dose using either a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis. SD, standard deviation.

References

    1. Zenobia C, Hajishengallis G. Basic biology and role of interleukin‐17 in immunity and inflammation. Periodontol 2000 2015; 69: 142–159. doi:.
    1. Sharma J, Balakrishnan L, Datta KK et al A knowledgebase resource for interleukin‐17 family mediated signaling. J Cell Commun Signal 2015; 9: 291–296.
    1. Raychaudhuri SP. Role of IL‐17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013; 44: 183–193.
    1. Griffiths CE, Reich K, Lebwohl M et al Comparison of ixekizumab with etanercept or placebo in moderate‐to‐severe psoriasis (UNCOVER‐2 and UNCOVER‐3): results from two phase 3 randomized trials. Lancet 2015; 386: 541–551. doi:.
    1. Berteau C, Scwarzenbach F, Donazzolo Y et al Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence 2010; 4: 379–388.
    1. Schwarzenbach F, Dao Trong M, Grange L et al Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence 2014; 8: 199–209.
    1. Kivitz A, Cohen S, Dowd JE et al Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self‐administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006; 28: 1619–1629.
    1. Paul C, Stalder JF, Thaҫi D et al Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 448–455.
    1. Bayas A. Improving adherence to injectable disease‐modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 2013; 10: 285–287.
    1. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009; 6: 995–1002.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe